Despite accumulating evidence supporting the value of local or systemic IGF-1 administration for treatment of diabetic neuropathy and other neurodegenerative disorders, such as Alzheimer’s, ALS and Rett syndrome, relatively little is still known about the role of endogenous IGF-1 in peripheral tissues. This evidence concerns the gene IGF1 and amyotrophic lateral sclerosis.